[Current news about epidemiology of syncytial respiratory virus infection].
At present, syncytial respiratory virus is the major agent of respiratory infections in pediatric patients. It can determine an important respiratory distress in particular children, as prematures with an gestational age <32 weeks, children affected by congenital heart diseases or bronchopneumonia dysplasia. In these patients, the prophylaxis with palivizumab is very important to prevent chronic pulmonary diseases.
Palumbo
Emilio
E
emipalu2003@yahoo.it
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D001988:Bronchiolitis / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007558:Italy / Q000453:epidemiology; D000069455:Palivizumab; D011024:Pneumonia, Viral / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab